



Tegaderm™

CHG Chlorhexidine Gluconate
I.V. Securement Dressings

Are your patients clearly protected against CRBSI?



3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressings

vs.



BioPatch® Disks with CHG

Tegaderm CHG I.V. Securement Dressings are the only transparent dressings cleared and proven to reduce catheter-related bloodstream infections (CRBSIs).


60% → reduction of CRBSIs

in a randomised control trial (RCT) of 1,879 subjects with 4,163 catheters.¹

Consistent application


Higher Percentage of CHG Correctly Applied²

Tegaderm CHG I.V. Securement Dressings




n=120






















BioPatch® Disks with CHG



n=128

The difference is clear.



Efficacy		Tegaderm CHG I.V. Securement Dressing	BIOPATCH® Disk with CHG
	Reduced CRBSIs Proven to reduce CRBSI in multiple RCT's and meta-analysis studies. ^{1,3,4,5,6}		
	Superior skin flora kill rate Tegaderm CHG I.V. Securement Dressing is proven to be more effective than BIOPATCH® Disk with CHG at each time point tested over the course of 10 days. ⁷		
	Superior skin flora regrowth suppression at 7 days Tegaderm CHG I.V. Securement Dressing is more effective at suppressing the regrowth of normal skin flora on prepped skin than BIOPATCH® Disk with CHG. ⁸		
	Suture site protection Tegaderm CHG I.V. Securement Dressing has been shown to reduce the number of microorganisms at the catheter insertion site, suture site, sutures and catheter surface. ^{*6}		
Safety & Ease of Use		Tegaderm CHG I.V. Securement Dressing	BIOPATCH® Disk with CHG
	Allows for constant site monitoring The 2021 Updates to the Infusion Nurses Society Infusion Therapy Standards of Practice recommends assessing the vascular access device (VAD) site and surrounding area to monitor skin, dressing and securement device integrity by inspection, and use palpation through the intact dressing to assess complications. ⁹		
	Superior placement accuracy rate Multiple studies have shown an improved CHG placement accuracy rate with the integrated Tegaderm CHG I.V. Securement Dressing compared to the placement of a BIOPATCH® Disk with CHG plus a dressing. ²		
	CHG gel pad is integral to a transparent dressing Since the CHG gel pad is integral to the Tegaderm CHG I.V. Securement Dressing, it cannot be put on upside down or forgotten and eliminates the need for extra steps to apply CHG separately from the cover dressing.		

*Tegaderm CHG I.V. Securement Dressings are not indicated to reduce bacterial colonisation of sutures or suture sites.

The choice is clear.

Antimicrobial protection. Transparent securement. All in one.

Extraluminal contamination, a potential cause of catheter-associated bloodstream infections (CABSI), happens when bacteria on the surface of the skin move along the outside of the catheter and enter through the insertion site. To help reduce this risk, 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressings provide immediate and continuous antimicrobial protection to an IV site.



Aligns to INS standards & NHMRC recommendations.^{9,10}

Infection reduction

3M™ Tegaderm™ CHG Dressings are clinically proven to reduce catheter-related bloodstream infections (CRBSI).¹⁰



60%
reduction
of CRBSIs

in a randomised controlled trial (RCT) of 1,879 subjects with 4,163 catheters.¹

Site visibility

Transparent dressing and gel pad enable early identification of potential complications at IV site and meet INS recommendation to assess the IV site and surrounding area by visual inspection.⁹

**Tegaderm CHG I.V.
Securement Dressing**



Catheter securement

Stabilisation border, keyhole notch and reinforcing tape strips designed to work together to minimise catheter movement or dislodgement.



3M has a variety of antimicrobial options to help reduce risks of extraluminal contamination.



**3M™ Tegaderm™ CHG
Chlorhexidine Gluconate
I.V. Securement Dressing,
1657R**



**3M™ Tegaderm™ CHG
Chlorhexidine Gluconate
I.V. Securement Dressing,
1658R**



**3M™ Tegaderm™ CHG
Chlorhexidine Gluconate
I.V. Securement Dressing,
1659R**



**3M™ Tegaderm™ CHG
Chlorhexidine Gluconate
I.V. Securement Dressing,
1660R**



**Entered on
the ARTG.**



**Classified as medical device
category Class III, offering quality
wear time and easy removal.**



**Do not contain skin
irritants and tackifiers
such as colophony.***

Important Safety Information for 3M™ Tegaderm™ CHG Dressings. Do not use 3M™ Tegaderm™ CHG Dressings on premature infants or infants younger than two months of age. Use of this product on premature infants may result in hypersensitivity reactions or necrosis of the skin. The safety and effectiveness of 3M™ Tegaderm™ CHG Dressings has not been established in children under 18 years of age. For full prescribing information, see the Instructions for Use (IFU). *Data on file.

Education and training to stay ahead of the curve.

Extraluminal contamination, a potential cause of catheter-associated bloodstream infections (CABSI), happens when bacteria on the surface of the skin move along the outside of the catheter and enter through the insertion site. To help reduce this risk, 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressings provide immediate and continuous antimicrobial protection to an IV site.

Contact your 3M representative to learn how we can help support:



Assessment



Education



Product training and compliance

Discover the ways how 3M™ can be a part of your overall vascular access care and management:

In Australia, visit: www.3M.com.au/medical or call 1300 363 878 or contact your 3M Representative.

In New Zealand, visit: www.3M.co.nz/medical or call 0800 808 182 or contact your 3M Representative.

References:

1. Timsit JF, et al. Randomized Controlled Trial of Chlorhexidine Dressing and Highly Adhesive Dressing for Preventing Catheter-Related Infections in critically ill adults. *American Journal of Respiratory and Critical Care Medicine* 2012; 186 (12):1272-1278.
2. Cynthia A. Kohan, MT, MS, CIC, John M. Boyce, MD. Published: *American Journal of Infection Control (AJIC)*; 2013; Vol 41, Issue 6, S142-S143; doi <http://dx.doi.org/10.1016/j.ajic.2013.03.283>.
3. Wei L, Li Y, Li X, Bian L, Wen Z, Li M. Chlorhexidine-impregnated dressing for the prophylaxis of central venous catheter-related complications: a systematic review and meta-analysis. *BMC Infect Dis.* 2019;19:(1). <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4029-9>.
4. Safdar N, O'Horo JC, Ghufuran A, et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: A meta-analysis. *Crit Care Med.* 2014;42(7):1703-1713
5. Eggimann P, Pagani JL, Dupuis-Lozeron E, et al. Sustained reduction of catheter-associated bloodstream infections with enhancement of catheter bundle by chlorhexidine dressings over 11 years. *Intensive Care Med.* (2019) 45:823-833. <https://doi.org/10.1007/s00134-019-05617-x>.
6. Karpanen T J, Casey A L, Das I, Whitehouse T, Nightingale P, Elliott T S J. Clinical evaluation of a Tegaderm CHG IV securement dressing on short term CVC's. *Journal of the Association for Vascular Access* 2016;September:21(3):133-138.
7. 3M Data on File (#09535).
8. Bashir MH, Olson LK, Walters SA. Suppression of regrowth of normal skin flora under chlorhexidine gluconate dressings applied to chlorhexidine gluconate-prepped skin. *Am J Infect Control.* 2012; 40(4): 344-8.
9. Gorski LA, Hadaway L, Hagle ME, et al. *Infusion Therapy Standards of Practice, 8th Edition.* J Infus Nurs. 10. 2021;44(suppl 1):S1-S224. doi:10.1097/NAN.0000000000000396. Refer to the document to view verbatim, comprehensive standards and practice recommendations.
10. National Health and Medical Research Council. *Australian Guidelines for the Prevention and Control of Infection in Healthcare. Standard 3.5.2.2. Intravascular access devices.* May 2019. Pg170.



3M Australia Pty Limited
Building A, 1 Rivett Rd
North Ryde, NSW 2113
1300 363 878
www.3M.com.au

3M New Zealand Limited
94 Apollo Drive
Rosedale, Auckland 0632
0800 80 81 82
www.3M.co.nz

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application.

© 2024 3M. All rights reserved. 3M and Tegaderm are trademarks of 3M. BIOPATCH is a trademark of Ethicon. Unauthorised use prohibited. All other marks are property of their respective owners.